La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !
Glenmark Pharmaceuticals Bilan de santé
Santé financière contrôle des critères 5/6
Glenmark Pharmaceuticals possède un total de capitaux propres de ₹78.5B et une dette totale de ₹12.3B, ce qui porte son ratio d'endettement à 15.7%. Son actif total et son passif total sont ₹143.6B et de ₹65.1B. L'EBIT de Glenmark Pharmaceuticals est ₹7.9B ce qui fait que son ratio de couverture des intérêts 1.8. Elle dispose de liquidités et de placements à court terme de ₹16.6B.
Informations clés
15.7%
Ratio d'endettement
₹12.31b
Dette
| Ratio de couverture des intérêts | 3.7x |
| Argent liquide | ₹16.59b |
| Fonds propres | ₹78.48b |
| Total du passif | ₹65.11b |
| Total des actifs | ₹143.59b |
Mises à jour récentes de la santé financière
Does Glenmark Pharmaceuticals (NSE:GLENMARK) Have A Healthy Balance Sheet?
Jun 16
Glenmark Pharmaceuticals (NSE:GLENMARK) Takes On Some Risk With Its Use Of Debt
Mar 09Is Glenmark Pharmaceuticals (NSE:GLENMARK) Using Too Much Debt?
Dec 07We Think Glenmark Pharmaceuticals (NSE:GLENMARK) Is Taking Some Risk With Its Debt
Jul 03Glenmark Pharmaceuticals (NSE:GLENMARK) Has A Somewhat Strained Balance Sheet
Mar 22We Think Glenmark Pharmaceuticals (NSE:GLENMARK) Can Stay On Top Of Its Debt
Jun 20Recent updates
This Is Why Glenmark Pharmaceuticals Limited's (NSE:GLENMARK) CEO Compensation Looks Appropriate
Sep 21Glenmark Pharmaceuticals (NSE:GLENMARK) Is Paying Out A Dividend Of ₹2.50
Sep 06Calculating The Fair Value Of Glenmark Pharmaceuticals Limited (NSE:GLENMARK)
Aug 06Does Glenmark Pharmaceuticals (NSE:GLENMARK) Have A Healthy Balance Sheet?
Jun 16Is Glenmark Pharmaceuticals Limited (NSE:GLENMARK) Expensive For A Reason? A Look At Its Intrinsic Value
May 08Glenmark Pharmaceuticals (NSE:GLENMARK) Takes On Some Risk With Its Use Of Debt
Mar 09Is Glenmark Pharmaceuticals (NSE:GLENMARK) Using Too Much Debt?
Dec 07Shareholders Will Probably Hold Off On Increasing Glenmark Pharmaceuticals Limited's (NSE:GLENMARK) CEO Compensation For The Time Being
Sep 23Glenmark Pharmaceuticals (NSE:GLENMARK) Will Pay A Dividend Of ₹2.50
Sep 17Glenmark Pharmaceuticals (NSE:GLENMARK) Has Announced A Dividend Of ₹2.50
Aug 30A Look At The Intrinsic Value Of Glenmark Pharmaceuticals Limited (NSE:GLENMARK)
Aug 28We Think Glenmark Pharmaceuticals (NSE:GLENMARK) Is Taking Some Risk With Its Debt
Jul 03A Look At The Fair Value Of Glenmark Pharmaceuticals Limited (NSE:GLENMARK)
May 28Glenmark Pharmaceuticals (NSE:GLENMARK) Has A Somewhat Strained Balance Sheet
Mar 22Estimating The Fair Value Of Glenmark Pharmaceuticals Limited (NSE:GLENMARK)
Feb 14An Intrinsic Calculation For Glenmark Pharmaceuticals Limited (NSE:GLENMARK) Suggests It's 37% Undervalued
Oct 12Shareholders Will Probably Hold Off On Increasing Glenmark Pharmaceuticals Limited's (NSE:GLENMARK) CEO Compensation For The Time Being
Sep 21Glenmark Pharmaceuticals (NSE:GLENMARK) Has Announced A Dividend Of ₹2.50
Aug 29We Think Glenmark Pharmaceuticals (NSE:GLENMARK) Can Stay On Top Of Its Debt
Jun 20There May Be Reason For Hope In Glenmark Pharmaceuticals' (NSE:GLENMARK) Disappointing Earnings
Jun 04An Intrinsic Calculation For Glenmark Pharmaceuticals Limited (NSE:GLENMARK) Suggests It's 27% Undervalued
May 05If You Like EPS Growth Then Check Out Glenmark Pharmaceuticals (NSE:GLENMARK) Before It's Too Late
Mar 25Analyse de la situation financière
Passif à court terme: Les actifs à court terme de GLENMARK ( ₹74.3B ) dépassent ses passifs à court terme ( ₹58.2B ).
Passif à long terme: Les actifs à court terme de GLENMARK ( ₹74.3B ) dépassent ses passifs à long terme ( ₹6.9B ).
Historique et analyse du ratio d'endettement
Niveau d'endettement: GLENMARK dispose de plus de liquidités que de sa dette totale.
Réduire la dette: Le ratio d'endettement de GLENMARK a été réduit de 64.7% à 15.7% au cours des 5 dernières années.
Couverture de la dette: Le flux de trésorerie opérationnel de GLENMARK est négatif, par conséquent la dette n'est pas bien couverte.
Couverture des intérêts: Les paiements d'intérêts de GLENMARK sur sa dette sont bien couverts par l'EBIT ( 3.7 x couverture).